



**SUMITOMO CHEMICAL INDIA LTD.**

Corporate Identity Number (CIN) – L24110MH2000PLC124224

**Corporate Office:** 13/14, Aradhana IDC,  
Near Virwani Industrial Estate, Goregaon (East),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel. : +91-22-4252 2200 / Fax : +91-22-4252 2380  
URL <http://www.sumichem-india.co.in>

SCIL/SEC/2025  
27<sup>th</sup> October, 2025

To,  
BSE Limited,  
Listing Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai-400001

The National Stock Exchange of  
India Listing Department,  
Exchange Plaza,  
Bandra Kurla Complex  
Bandra East,  
Mumbai - 400 051

Dear Sirs,

**Sub: Investor Presentation on Financial Results for the  
quarter and half year ended 30<sup>th</sup> September, 2025**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith investor presentation on the Financial Results of the Company for the quarter and half year ended 30<sup>th</sup> September, 2025.

Kindly do the needful to display the same on your website.

Thanking you,

Yours faithfully,  
For Sumitomo Chemical India Limited

Deepika Trivedi  
Company Secretary

Encl: a/a

# A YEAR OF RESURGENCE

## Sumitomo Chemical India Limited

---

Investor Presentation - September 2025



This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Sumitomo Chemical India Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.





# Financial Performance & Key Highlights

---







# Performance Highlights – Quarter & YTD

Q2FY26 vs Q2FY25



H1FY26 vs H1FY25




Given the seasonality in the business, it is best monitored on an annual basis


- ✓ The South-West Monsoon, though strong overall, **turned challenging during the key consumption period**. After a brief dry spell in early July, persistent and **widespread rains from mid-July through September disrupted normal agronomic activities**, impacting pesticide applications across several regions.
  - **Farmers missed a few scheduled spray cycles** in major kharif crops due to prolonged wet conditions and restricted field access. Excess moisture also caused localized crop damage in cotton, groundnut, soybean, rice, and chillies, leading to **reduced pest incidence** and subdued agrochemical consumption.
- ✓ The quarter witnessed a **softer performance**, largely reflecting the adverse weather impact. While price realization remained stable, **lower volumes led to moderated operating leverage and margins**.
- ✓ Despite this, the company's **disciplined channel management** and **prudent working capital practices** ensured business continuity without material sales returns or collection delays — in contrast to broader industry trends marked by inventory build-up and payment stress.
- ✓ **Export performance** was impacted by **softer offtake** in select markets such as **Africa and Latin America**, though demand in the U.S. and Europe remained steady. The decline was primarily due to shipment deferrals and product-specific factors in certain geographies.
- ✓ The newly launched rice herbicide '**Lentigo**' continued to gain encouraging traction, while '**Excalia Max**' and **other key molecules maintained strong market acceptance**. Core brands across insecticides and herbicides sustained leadership positions and contributed to resilience in the overall mix. In the Environmental Health Division, branded and custom solution products registered healthy growth off a low base.
- ✓ On a **cumulative H1FY26 basis**, SCIL maintained **growth momentum with both revenue and profitability improving** versus the corresponding period last year. The company's strong portfolio, field connect, and supply discipline helped offset the transient seasonal headwinds.
- ✓ **Reservoir levels across key agri-belts remain healthy**, providing a favourable base for the upcoming **rabi season**, supported by adequate soil moisture, good groundwater recharge, and sufficient labour availability. The company expects **improved rural sentiment** and **steady recovery in agri-input demand in H2FY26**.
- ✓ SCIL remains focused on **portfolio differentiation, deepening farmer engagement**, and **operational agility**, positioning itself to capture seasonal recovery and sustain long-term growth in India's evolving agri-input landscape.



Subdivision-wise monsoon rainfall during June-September 2025



Cumulative normal vs. actual rainfall (Mm) in Monsoon season 2025



Distribution of rainfall over 36 sub-divisions in June-September 2025

| Category        | % of LPA  | No. of sub-divisions | Subdivisional % area of country |
|-----------------|-----------|----------------------|---------------------------------|
| Large Excess    | above 160 | 2                    | 10%                             |
| Excess          | 120-159   | 12                   | 35%                             |
| Normal          | 81-119    | 19                   | 46%                             |
| Deficient       | 41-80     | 3                    | 9%                              |
| Large Deficient | 0-40      | 0                    | 0%                              |
| No Rain         | 0         | 0                    | 0%                              |
| Total           |           | 36                   | 100%                            |

Source: IMD; CEIC; ICRA Research



**CUFLOW™**  
Fungicide



**SANTANA®**  
Insecticide



**RUMPUS®**  
Fungicide



**SUMI BLUE  
DIAMOND™**  
Plant Growth  
Regulator



**PROMALIN®**  
Plant Growth  
Regulator



**KORKO®**  
Insecticide



**DERECHO®**  
Fungicide



**YUNICO**  
Insecticide



**YUNICO FLOW**  
Insecticide



**BLOG**  
Herbicide



**MESHI**  
Insecticide



**PORTION**  
Insecticide



**ORMIE**  
Fungicide











# 'Every Day Farmers' Day' Campaign - Highlights



## Campaign Overview

A structured Demand Generation campaign conducted in Kharif and Rabi seasons respectively, aimed at creating sustained field and market momentum.

## Impact

- ✓ **Focus on Demand Generation:** Drove consistent market pull through direct farmer engagement.
- ✓ **Farmer-Centric Engagements:** Meetings with 25+ farmers ensured scale and impact.
- ✓ **Weekly Planning & Execution:** Weekly execution plans with rigorous follow-up for field consistency.
- ✓ **Leadership-Driven Participation:** Involvement across all levels, including top management.
- ✓ **Frontline Ownership:** Frontline managers lead with strong focus on crop segment engagement.
- ✓ **Gap Identification & Resolution:** Helped to identify and address operational gaps promptly.
- ✓ **Industry Benchmark:** A best-practice campaign known for discipline and commitment.
- ✓ **Digital-First Tracking System:** Used in-house tools to track and monitor field activities at real-time.
- ✓ **Transparent Progress Monitoring:** Tracked progress on daily, weekly, and monthly basis.

Total Meetings

1,336

**EDFD Mega Week  
2025 - 26**

Total Farmers +  
Channel Partner Connects

45,317

**EDFD Mega Week  
2024 - 25**

Total Meetings

1,472

Total Farmers +  
Channel Partner Connects

61,044

### Big Leap in EDFD Mega Week (14<sup>th</sup> to 19<sup>th</sup> July 2025) – from 2024

- ✓ We recorded a **35%** increase in farmer + Channel Partner connects compared to 2024 Mega Week.
- ✓ Meetings rose by **10%**, showing better planning and stronger execution.



# 'Every Day Farmers' Day' Campaign






# Consolidated Profit & Loss Account Statement


| Particulars (Rs. Crs)                            | Q2FY26       | Q2FY25       | YoY             | Q1FY26         | QoQ            | H1FY26         | H1FY25         | YoY            |
|--|--------------|--------------|-----------------|----------------|----------------|----------------|----------------|----------------|
| <b>Revenue from Operations</b>                   | <b>929.8</b> | <b>988.3</b> | <b>-6%</b>      | <b>1,056.8</b> | <b>-12%</b>    | <b>1,986.6</b> | <b>1,827.2</b> | <b>9%</b>      |
| COGS   | 529.2        | 567.6        |                 | 654.4          |                | 1,183.7        | 1,080.1        |                |
| <b>Gross Profit</b>                              | <b>400.6</b> | <b>420.7</b> | <b>-5%</b>      | <b>402.4</b>   | <b>0%</b>      | <b>802.9</b>   | <b>747.1</b>   | <b>7%</b>      |
| <b>Gross Profit %</b>                            | <b>43.1%</b> | <b>42.6%</b> | <b>52 bps</b>   | <b>38.1%</b>   | <b>501 bps</b> | <b>40.4%</b>   | <b>40.9%</b>   | <b>-47 bps</b> |
| Employee Expenses                                | 69.5         | 66.1         |                 | 70.8           |                | 140.3          | 131.6          |                |
| Other Operating Expenses                         | 113.0        | 109.3        |                 | 112.3          |                | 225.4          | 209.1          |                |
| <b>Operating EBITDA</b>                          | <b>218.0</b> | <b>245.3</b> | <b>-11%</b>     | <b>219.2</b>   | <b>-1%</b>     | <b>437.2</b>   | <b>406.4</b>   | <b>8%</b>      |
| <b>EBITDA Margin</b>                             | <b>23.4%</b> | <b>24.8%</b> | <b>-137 bps</b> | <b>20.7%</b>   | <b>271 bps</b> | <b>22.0%</b>   | <b>22.2%</b>   | <b>-23 bps</b> |
| Other Income                                     | 38.8         | 31.2         |                 | 38.8           |                | 77.6           | 57.2           |                |
| Depreciation                                     | 16.8         | 15.7         |                 | 15.7           |                | 32.5           | 30.6           |                |
| <b>EBIT</b>                                      | <b>240.1</b> | <b>260.8</b> | <b>-8%</b>      | <b>242.3</b>   | <b>-1%</b>     | <b>482.3</b>   | <b>433.0</b>   | <b>11%</b>     |
| <b>EBIT Margin</b>                               | <b>25.8%</b> | <b>26.4%</b> | <b>-57 bps</b>  | <b>22.9%</b>   | <b>290 bps</b> | <b>24.3%</b>   | <b>23.7%</b>   | <b>58 bps</b>  |
| Interest   | 2.2          | 1.2          |                 | 1.7            |                | 3.9            | 2.4            |                |
| <b>Profit Before Tax</b>                         | <b>237.8</b> | <b>259.6</b> | <b>-8%</b>      | <b>240.6</b>   | <b>-1%</b>     | <b>478.4</b>   | <b>430.6</b>   | <b>11%</b>     |
| <b>PBT Margin</b>                                | <b>25.6%</b> | <b>26.3%</b> | <b>-68 bps</b>  | <b>22.8%</b>   | <b>281 bps</b> | <b>24.1%</b>   | <b>23.6%</b>   | <b>52 bps</b>  |
| Tax  | 60.1         | 67.0         |                 | 62.5           |                | 122.6          | 111.4          |                |
| <b>Net Profit</b>                                | <b>177.8</b> | <b>192.5</b> | <b>-8%</b>      | <b>178.1</b>   | <b>0%</b>      | <b>355.9</b>   | <b>319.2</b>   | <b>11%</b>     |
| <b>Net Profit Margin</b>                         | <b>19.1%</b> | <b>19.5%</b> | <b>-36 bps</b>  | <b>16.9%</b>   | <b>227 bps</b> | <b>17.9%</b>   | <b>17.5%</b>   | <b>44 bps</b>  |
| Other Comprehensive Income                       | 1.4          | -2.5         |                 | -1.3           |                | 0.1            | -2.1           |                |
| <b>Total Comprehensive income for the period</b> | <b>179.2</b> | <b>190.0</b> | <b>-6%</b>      | <b>176.8</b>   | <b>1%</b>      | <b>355.9</b>   | <b>317.1</b>   | <b>12%</b>     |

Given the seasonality in the business, it is best monitored on an annual basis


Product Breakup




Geographic Breakup



Segment Breakup



Bulk & Branded



\* Animal Nutrition Division (AND) and Environmental Health Division (EHD)

# Consolidated Balance Sheet

| Assets (Rs. Crs)                          | Sep-25         | Mar-25         |
|---|----------------|----------------|
| <b>Non-Current Assets (A)</b>             | <b>893.6</b>   | <b>944.1</b>   |
| Property, Plant and Equipment             | 408.6          | 425.8          |
| Capital work-in-progress                  | 14.4           | 9.4            |
| Right to use an Asset                     | 69.1           | 63.5           |
| Goodwill                                  | 60.4           | 60.4           |
| Other Intangible Assets                   | 8.0            | 6.7            |
| Intangible Assets under Development       | 17.8           | 19.1           |
| <b>Non-Current Financial Assets</b>       |                |                |
| (i) Investments                           | 128.1          | 67.1           |
| (ii) Loans & other financial assets       | 154.2          | 247.9          |
| Deferred tax Asset (net)                  | 0.6            | 1.2            |
| Non-Current tax Assets (net)              | 25.9           | 37.5           |
| Other non-current Assets                  | 6.4            | 5.7            |
| <b>Current Assets (B)</b>                 | <b>3,544.9</b> | <b>3,020.3</b> |
| Inventories                               | 613.3          | 703.7          |
| <b>Current Financial Assets</b>           |                |                |
| (i) Investments                           | 1,090.9        | 457.2          |
| (ii) Trade receivables                    | 903.4          | 783.4          |
| (iii) Cash and cash equivalents           | 40.9           | 38.2           |
| (iv) Bank balances other than (iii) above | 1.6            | 4.6            |
| (v) Loans                                 | 205.9          | 101.9          |
| (vi) Other financial assets               | 538.8          | 814.5          |
| Other Current Assets                      | 150.2          | 116.9          |
| <b>Total Assets (A+B)</b>                 | <b>4,438.5</b> | <b>3,964.4</b> |

| Equity & Liabilities (Rs. Crs)                | Sep-25         | Mar-25         |
|---|----------------|----------------|
| <b>EQUITY (A)</b>                             | <b>3,201.1</b> | <b>2,905.1</b> |
| Equity Share Capital                          | 499.1          | 499.1          |
| Other Equity                                  | 2,698.3        | 2,402.0        |
| Non-controlling Interests                     | 3.7            | 3.9            |
| <b>Non-Current liabilities (B)</b>            | <b>101.6</b>   | <b>94.2</b>    |
| <b>Non-current Financial liabilities</b>      |                |                |
| Lease Liabilities                             | 37.2           | 32.8           |
| Provisions                                    | 36.3           | 34.8           |
| Deferred tax liabilities (net)                | 28.1           | 26.6           |
| Non-current Tax Liabilities                   | 0.1            | -              |
| <b>Current liabilities (C)</b>                | <b>1,135.8</b> | <b>965.2</b>   |
| <b>Current Financial liabilities</b>          |                |                |
| (i) Borrowings                                | 0.0            | 0.0            |
| (ii) Trade Payables                           | 483.8          | 489.4          |
| (iii) Lease Liabilities                       | 21.0           | 19.1           |
| (iii) Other financial liabilities             | 525.4          | 377.3          |
| Other current liabilities                     | 58.9           | 64.7           |
| Provisions                                    | 5.3            | 9.0            |
| Current tax liabilities                       | 41.4           | 5.6            |
| <b>Total Equity &amp; Liabilities (A+B+C)</b> | <b>4,438.5</b> | <b>3,964.4</b> |

NIL borrowings

Cash, Cash Equivalents & Liquid Investments of ~Rs. 2,089 Crs as on 30<sup>th</sup> September 2025

# Consolidated Working Capital Movement

| Particulars (Rs. Crs)  | Sep-25*      | Jun-25*      | Change<br>(Sep-25 to<br>Jun-25) | Mar-25*      | Change<br>(Sep-25 to<br>Mar-25) | Sep-24*      | Change<br>(Sep-25 to<br>Sep-24) |
|--|--------------|--------------|---------------------------------|--------------|---------------------------------|--------------|---------------------------------|
| Inventory (A)  | 613.3        | 648.6        | -35.3                           | 703.7        | -90.4                           | 564.3        | 49                              |
| Inventory Days ( <i>Inventories/ COGS* No. of days in period</i> ) (i)                                     | 95           | 90           |                                 | 138          |                                 | 96           |                                 |
| <b>Trade Receivables (B)</b>   | <b>903.4</b> | <b>882.1</b> | 21.3                            | <b>783.4</b> | 120                             | <b>944.5</b> | -41.1                           |
| <b>Trade Receivables Days (<i>Trade Receivables / Revenue*No. of days in period</i>) (ii)</b>              | <b>83</b>    | <b>76</b>    |                                 | <b>91</b>    |                                 | <b>95</b>    |                                 |
| Trade Payables (C)   | 483.8        | 574.9        | -91.1                           | 489.4        | -5.6                            | 490.4        | -6.6                            |
| Trade Payables Days ( <i>Trade Payables/ COGS*No. of days in period</i> ) (iii)                            | 75           | 80           |                                 | 96           |                                 | 83           |                                 |
| Other Financial Liabilities (D)  | 525.4        | 505.2        | 20.2                            | 377.3        | 148.1                           | 447.4        | 78                              |
| Other Financial Liabilities Days ( <i>Other Current Liabilities / Revenue*No. of days in period</i> ) (iv) | 48           | 44           |                                 | 44           |                                 | 45           |                                 |
| <b>Net Working Capital (A+B-C-D)</b>   | <b>507.5</b> | <b>450.6</b> | <b>56.9</b>                     | <b>620.3</b> | <b>-112.8</b>                   | <b>571.0</b> | <b>-63.5</b>                    |
| <i>Net Working Capital Days (i + ii – iii – iv)</i>  | 55           | 43           |                                 | 89           |                                 | 62           |                                 |

## Key Highlights

- ✓ In term of overall net working capital days, there has been reduction of 34 days & 7 days as on September '25 compared to that of March '25 and September '24 respectively. The y-o-y reduction in WC days was primarily led by better receivable management, with a sharper reduction in receivable days relative to the decrease in payable days. Inventory days remained broadly stable, reflecting consistent and efficient inventory planning.
- ✓ Cash & cash equivalent as on 30<sup>th</sup> September 2025 stood at Rs. 2,089 crore. Focused efforts towards improving collections - Collection during H1FY26 of ~Rs. 2,277 crores as compared to Rs. 1,999 crores during H1FY25, reflecting consistent focus on receivable management and disciplined cash flow practices despite challenging seasonal conditions.


Given the seasonality in the business, it is best monitored on an annual basis

\* No. of Days in period: Sep-25 – 92, Jun-25 – 91 days, Mar-25 – 365 days, Sep-24 – 92 days

# Consolidated Cash Flow Statement

| Cash Flow Statement (Rs. Crs)   | Half Year ended 30-Sep-25 | Half Year ended 30-Sep-24 |
|---|---------------------------|---------------------------|
| <b>Net Profit Before Tax</b>  | <b>478.4</b>              | <b>430.6</b>              |
| Adjustments for: Non-Cash Items / Other Investment or Financial Items | -25.7                     | -17.2                     |
| <b>Operating profit before working capital changes</b>                | <b>452.7</b>              | <b>413.4</b>              |
| Changes in working capital  | 55.6                      | 15.6                      |
| <b>Cash generated from Operations</b>                                 | <b>508.3</b>              | <b>429.0</b>              |
| Direct taxes paid (net of refund)                                     | 73.1                      | 70.9                      |
| <b>Net Cash from Operating Activities</b>                             | <b>435.2</b>              | <b>358.2</b>              |
| <b>Net Cash from Investing Activities</b>                             | <b>-359.9</b>             | <b>-298.6</b>             |
| <b>Net Cash from Financing Activities</b>                             | <b>-72.2</b>              | <b>-53.2</b>              |
| <b>Net Increase /(Decrease) in Cash and Cash equivalents</b>          | <b>2.6</b>                | <b>6.5</b>                |
| Add: Cash & Cash equivalents at the beginning of the period           | 38.2                      | 46.6                      |
| <b>Cash &amp; Cash equivalents at the end of the period</b>           | <b>40.9</b>               | <b>53.1</b>               |





# Company Overview

---



# Journey to 14x Growth in India

**SCIL – Vision & Mission**

**Formidable Player in the Indian  
Agrochemicals Space**

**Diversified & De-risked Portfolio Across  
the Agro-Chem Value Chain**

**Strong Brand and Well-Entrenched  
Distribution Network**

**Strategically Located Manufacturing  
Facilities**


**Strong Focus on R&D, Process Innovation  
and Safety, Health and Environment (SHE)**

**Autonomous Board with Vast Industry  
Experience**

**Growth Strategies**



# SCIL - Vision & Mission



## Vision & Values

### Vision:

- To be a trusted market leader in Indian crop-protection sector
- To develop a vibrant corporate culture
- Endeavor to achieve success and sustainability through innovation & excellence

### Core Values:

- Innovation
- Excellence
- Integrity
- Respect & value all stakeholders
- Customer focus
- People focus
- Sustainability



## Mission

### Marketing and Sales:

- Further penetration into Indian market & take leadership; expand exports
- Strengthen Sales Force, Distribution and Product Portfolio



### Manufacturing:

- Supplying the most competitive products with safe and stable operation and meet demand
- Strengthen Procurement Power
- Expand Manufacturing Functions

### Management & Support:

- Establishing the most efficient organization to support business growth and alignment with SCC
- Develop administrative efficiency while ensuring internal controls
- Full & Strict Compliances
- Value Creation for all stakeholders

# Journey to 14x Growth in India in last 15 years





5  
Manufacturing  
Facilities

14  
Technical  
Actives

15,000+ Direct  
Distributors &  
60 Depots




200+ Brands  
700+ SKUs

25+ Patents  
200+ Registrations

1600+ Employees  
1500+ FDOs#

Grown 14x+ over FY11-25




#FDOs - Field Development  
Officers (contractual)

Key Products

| Product Name       | Product Category       | Indicative Use             |
|--------------------|------------------------|----------------------------|
| Fenpropathrin      | Insecticide            | Paddy, Cotton, F&V         |
| Glyphosate         | Herbicide              | Tea Gardens, non-cropped   |
| Profenophos        | Insecticide            | Cotton, Soya bean          |
| Pyriproxyfen       | Insecticide            | Cotton                     |
| Clothianidin       | Insecticides           | Vegetables                 |
| Tebuconazole       | Fungicides             | Wheat, Soya bean, Chilli   |
| Gibberallic Acid   | Plant Growth Regulator | Citrus Fruits              |
| Aluminum Phosphide | Fumigant               | Warehousing of Food Grains |
| Chlorpyriphos      | Insecticide            | Paddy, Beans, Gram         |
| DL-Methionine      | Animal Nutrition       | Poultry                    |



# Diversified & De-risked Portfolio Across the Agro-Chem Value Chain

Well-Diversified across multiple dimensions



Diversified Portfolio Across Segments

Geographic Diversification with Exports to ~50 countries



- ✓ Greater focus on high growth, stable and high profitable segments such as **Herbicides, PGR, Bio-rational products**
- ✓ Increasing contribution from PGR segment and offerings for both Kharif and Rabi crops to reduce seasonality in the business
- ✓ One of the highest proportion of environmentally-friendly products in the Industry

- ✓ **Top 10 products contributes less than 45% of Total Revenue on annual basis**
- ✓ **No product / molecule contributes more than ~15% of Total Revenue on annual basis**
- ✓ **Diversified across key crops - Concentrated efforts on fruits & vegetables, paddy, cotton and other high growth segments**

# Strong Brand and Well-Entrenched Distribution Network

✓ **Strong brand** with market leading position across various product categories

✓ **Dual brand portfolio** can offer products at all price points serving multiple customer sub-segments

✓ **In-depth knowledge** of own research products, **proven go-to-market strategy and deep farmer connect** facilitates launch of Speciality products

✓ **On-field demonstration of products, training of farmers** in using the products, building awareness among stakeholders in relation to the products

✓ **Pan-India distribution network** ensures strong presence with both retailers and farmers and **on-time feedback mechanism**

✓ **Scale and diversity** of product offerings lead to **superior bargaining power** with distributors and provides **one-stop solution for farmers**

✓ Expanded teams for **strategic marketing, demand generation, product development and regulatory affairs** to focus on future growth



**26** States



**15,000+**  
Distributors



**4.4 million+**  
Farmer Connect through  
physical meetings  
**20 million+**  
Digital Connect




**60** Depots



**~40,000**  
Dealers



**~600**  
Sales Team





# Expanding Brand Visibility and Connect



- ✓ **Wide range of generics and speciality products** for Increased crop presence and providing crop protection solutions
- ✓ **More than 1,500+ Relationship managers** connecting to **4.4 million+ farmers** throughout crop cycle
- ✓ Over **200 brands** covering maximum of crops and pest segments
- ✓ **15,000+ distributors; 40,000+ dealers and 60 Depots** help in expanding brand visibility and connect
- ✓ More than **600+ Qualified and skilled managers** in Sales, Marketing and customer support
- ✓ Company with **20+ mega brands** with high brand recall
- ✓ Healthy geographical Brand coverage **throughout India** including North East and J&K
- ✓ Optimum use of **advertising media** with increased Digital Platforms presence



# Resurging Through Phygital Transformation (1/2)

## Rural India: Digitally Connected, Strategically Engaged

With rural India witnessing a digital revolution—boasting over 442 million internet users and 425 million smartphone owners—SCIL has strategically positioned itself to lead this wave. Our data-driven digital marketing framework now serves as a powerful catalyst for business growth and rural community engagement.

- ✓ 814+ localized landing pages across key dialects, optimized for voice search and rural accessibility
- ✓ 639 precision-targeted digital campaigns mapped to crop cycles, geographies, and farmer needs
- ✓ 14.2 crore digital touchpoints, contributing significantly to lead generation, brand affinity, and dealer inquiries
- ✓ 17.2% reduction in engagement costs, driven by smart segmentation and programmatic delivery
- ✓ Partnerships with hyper- local influencers, enhancing message authenticity
- ✓ Field activity tracking Apps- Sumitomo Connect & Sumitomo Field Connect

## The Power of Phygital Field Days

Our Field Days evolved into immersive Phygital experiences—where digital interactivity met on-ground demonstration. A standout initiative was the “Live Field Days”, allowing farmers, distributors, and field executives to engage in real-time with our agronomists, R&D experts, Portfolio Managers, Demand Generation and Sales teams.

These live sessions:

- ✓ Enhanced farmer trust through live Q&A and transparent product demonstrations
- ✓ Drew strong participation from farmers, channel partners, and field teams across regions, fostering vibrant two-way engagement during each session








# Strategically Located Manufacturing Facilities

Connectivity to Major Cities and Proximity to Main Highways, Ports Reduces Logistic Time and Costs



| Plant Location | Area (acres) | Segment Served   | Product Manufactured   |
|----------------|--------------|--|--|
| Bhavnagar      | ~58          | Manufacturing of Technical Grade Pesticides and Formulations                             | <b>Technical Grade Products:</b><br>Chlorpyrifos, Profenophos, Glyphosate, Tebuconazole Tech, Quinalphos, Imidacloprid, Thiacloprid, Acetamiprid, Byspyribac Sodium, Fluroxypyr, Aluminium Phosphide, Zinc Phosphide, Sulphur WDG, Fenpropathrin |
| Gajod          | ~120         | Production and manufacturing of Metal Phosphides, Sulphur WDG and other WDG formulations |  |
| Tarapur        | ~5           | Production and manufacturing of Active Ingredients                                       |  |
| Vapi           | ~6           | Formulation & Packaging  |  |
| Silvassa       | ~3           | Formulation of Glyphosate and Other Speciality Products                                  | Formulations for above TG products and several other speciality and generic products   |

- **Overall Optimal capacity utilization ~ 80% to 90% for TGAi's**
- **Bought 2 additional private owned land parcels for future expansion:**
  - ~20 acre adjoining our existing Bhavnagar site
  - ~50 acre at a prime location at Dahej within Chemical Zone (recently received environmental clearance)

Maps not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness

## Second Plant for a key SCC innovated product at Bhavnagar site for global requirements

SCIL has received board approval to set up a second plant for an important SCC innovated product for global requirements at existing Bhavnagar site

Brownfield expansion at existing Bhavnagar site – second plant for the same product within two years of first plant

Approximately ₹55 crore

To build on the success of the first plant, which demonstrated high utilization, world-class quality, and strong cost competitiveness

Q4FY27 (Jan–Mar 2027)

### Product

### Project Type

### Investment

### Objective

### Target Completion & Commercialization

## Production of a newly launched SCC innovated molecule at Tarapur site

SCIL has received board approval to manufacture a newly launched SCC innovated molecule at its Tarapur site

SCIL will undertake equipment modification and line readiness at its Tarapur facility for this newly launched product


Around ₹10 crore

In order to demonstrate SCIL's capability to manufacture in India a newly launched SCC innovative molecule, as also to meet the expected domestic demand of this newly launched product

Q4FY27 (Jan–Mar 2027)

## R&D: End-to-End Product Development Capabilities

- ❑ **3 fully equipped, DSIR approved R&D labs** located at Mumbai, Bhavnagar and Gajod capable of synthesis, technical product and formulation development; Soil Health Research Laboratory and in-house field trials
- ❑ R&D Team comprises of **75+** qualified and dedicated engineers & scientists of which **10+** are PhDs with more than **15 years** of Experience
- ❑ **25+ patents** granted across various geographies; 9 applications filed
- ❑ R&D facilities to gain capability for creating new processes and new combinations using **SCC Japan's chemistries** which would help improve production processes and efficiency



Bhavnagar, Synthesis Lab



Bhavnagar, R&D Analytical lab



Bhavnagar, Soil Health Research Lab













Bhavnagar, Biopesticides Unit



# Thrust on Safety, Health and Environment (SHE)

## Quality Certifications Ensure Consistent product quality and healthy working environment at manufacturing sites

-  Four Start Export House by Ministry of Commerce and Industry
-  Authorized Economic Operator AEO (Tier-2) Certification
-  ISO:9001:2015, ISO-14001:2015 and OHSAS18001:2007 for the manufacturing sites at Bhavnagar, Gajod, Tarapur and Silvassa; ISO:9001:2015 at Vapi
-  A8000 Certification for Social Accountability in Bhavnagar and Gajod
-  Efforts focused on reducing effluent load and effluent treatment cost, for staying innovative and competitive in the market
-  The quality of the products is maintained and upgraded to the applicable national and international standards through rigorous pursuit of Six Sigma initiative
-  Focused on energy conservation and energy cost reduction: 65% of total power requirement through wind and solar power generation plants
-  Expanding solar power plant capacity in line with towards green energy would also help in reducing dependence on outsourced power as well as in energy cost reduction
-  3R Principle: Recovery – Recycle – Reuse
-  Safety audit, training programmes and other safety management processes and programmes are carried out/conducted at regular intervals



## Abiding by SCC Japan's EHS Policies



Dr. Vikram Sarabhai award for developing green technology from department of Science and Technology, Government of Gujarat



Certificates of appreciation received ten times from jointly by Gujarat Safety Council and Dish



Government of Gujarat for achieving 10 lakh accident free man-hours



Certificates of merits received from jointly by Gujarat Safety Council and Dish Government of Gujarat for achieving 20 lakh accident free man-hours





Certificates of honour received two times jointly by Gujarat Safety Council and Dish Government of Gujarat for achieving 30 lakh accident free man-hours


**Focus on purity, quality and timely delivery of products to the customer**

# Awards & Accolades


## Quality Certifications Ensure Consistent product quality and healthy working environment at manufacturing sites


 Jamnalal Bajaj Award for “Fair Business and Practices”

 Chemexcil Best Exporter's award: 2017-18 received in 2023

 First award for export of organic and inorganic chemicals

 ICMA award for innovation and purposeful programs for social progress


 First Sir P.C. Ray award for development of products and process with indigenous technology


 Punjab Haryana Delhi Chamber of Commerce and Industries award for ethical business

 Winner active ingredient trophy and certificate from M/s. Bayer


 Trishul award for the excellent performance for exports in international markets


 Global CSR award from SCC for one of our Integrated Village Development Programme


 ICMA award for innovation and purposeful programs for social progress


 Shramveer award for improvement of product efficiency received from national level Delhi

 Vishwakarma Rashtriya Puraskar received for process development

 National Safety Award by Labour Ministry, Government of India for safety performance


 Shramveer Award to employees from Labour Ministry, state level received six times

 Shram Bhushan Award to employees received five times

 Shram Ratna to employees, received seven times

 Shram Shri award to employees received three times

 Gujarat State Safety Certificate for safety commitment

 CSR Award from Federation of Gujarat Industries

Focus on **purity, quality and timely delivery** of products to the customer



# Autonomous Board with Vast Industry Experience



**Dr. Mukul Govindji Asher**  
**Chairman and Independent Director**

- Professorial Fellow at Lee Kuan Yew School of Public Policy at the National University of Singapore
- Advisor to Govts in Asia on tax policy & pension reforms; and to multi-lateral institutions including IMF, Asian Development Bank, PFRDA of India, Govt of Gujarat, & World Bank
- Member of the panel to review Crawford School of Public Policy at Australian National University



**Preeti Gautam Mehta**  
**Independent Non-executive Director**

- 32 years of experience in corporate laws, foreign investment and collaborations, mergers and acquisitions and private equity investments, banking, franchising and hospitality



**N. Sivaraman**  
**Independent Director**

- Qualified Chartered Accountant with close to 40 years of experience as finance professional and business and organizational leader.
- He had over 35 years of successful career with Larson & Toubro Group holding position of President and Whole-time Director of L&T Finance Holdings Limited and board membership of L&T Infrastructure Finance Limited where he played pivotal role. Managing Director and Group CEO at ICRA Limited and COO of IL&FS Limited



**Ninad Dwarkanath Gupte**  
**Non-executive Director**

- Experience of 45 years in management of companies operating in fine chemicals, performance chemicals, industrial chemicals & agrochemicals
- Held senior positions at Excel Industries, BASF India, Herdillia Chemicals and worked as MD of Cheminova India and Agrocel Industries and as Joint MD of Excel Crop Care

# Autonomous Board with Vast Industry Experience



**Tadashi Katayama**  
**Non-executive Director**

- MBA from Vanderbilt University, U.S.A. and a Master's degree from Kyoto University in Japan
- Associated with SCC Japan since 1992 in the Health and Crop Science business unit in various positions
- President of Agro Life Sciences sector at SCC Japan



**Masanori Uzawa**  
**Non-executive Director**

- MBA from University of Virginia, USA and a Bachelor's degree from the University of Tokyo in Japan
- Associated with SCC Japan and has experience of over 20 years in the areas of strategy, planning and business development for crop protection & other chemical businesses.
- Head of Agro Solutions Division International



**Chetan Shantilal Shah**  
**Managing Director**

- Commerce graduate from the University of Mumbai and holds a master's degree in Business Administration from North Rope University in the USA
- Over 45 years of industry experience in various leadership and senior management roles



**Sushil Champaklal Marfatia**  
**Executive Director**

Chartered Accountant with over 44 years of industry experience  
Worked with New Chemi Industries Limited for 33 years which was later merged with the Company



**Dr Suresh Ramachandran**  
**Deputy Managing Director**

- Ph.D. in Entomology from The University of Georgia, USA
- 26 years of expertise - Sales and Distribution, Product Management, Regulatory, Business Management, R&D, Six Sigma & Enterprise Resource Planning, in Crop Protection & Seeds Business.

Board is supported by a strong and experienced management team associated with Company since long

# Growth Strategies



## Continued Investment in R&D and Pipeline

- Aim to invest in seamless integration of R&D between SCIL and SCC units which would help improve our production processes, enhancing yields and efficiency
- Introduce new products as per market demand



## Capacity Expansion

- Driving operational efficiencies maintaining highest safety standards and Responsible Care compliances
- Invest ~15% of consolidated EBITDA every year for upgradation of manufacturing facilities and capacity expansion to cater to strong domestic/global demand



## Further Brand Development

- Investments for marketing of new and existing products and brands
- On-field demonstrations, training of farmers for building ground-level demand generation supported by digital marketing
- Extraordinary preparations for new product launches underway



## Product Pipeline

- Multiple products coming from initiatives
- Global Speciality Proprietary products to be launched in India
- New combination products / pre-mixtures currently under development for domestic and exports
- Off-patent products under development for domestic and exports
- Technical products for manufacturing and exports



## Expand Export Business

- Enhance exports in regions like Africa Leverage SCC's Global supply chain and marketing network to drive exports in Latin America, Asia and Europe

## Achieving Market Leadership in India

- Balanced portfolio of specialty products (including futuristic green products) and off-patent products
- Consolidate position as best agro-chemical marketer in India
- Strive for manufacturing excellence & expand Make in India Projects
- Making organization ready to handle future challenges (Transform)
- Sustainable and healthy financial results (Harvest)

Leverage expertise in successful product launches, demand generation and manufacturing capacity expansions to fuel future growth




# Financial Performance & Key Takeaways

---




# Historical Performance Highlights


Revenue (Rs Crs)




EBITDA (Rs. Crs) & EBITDA Margin (%)




PAT (Rs Crs)




Networth (Rs Crs)



RoCE (%)^



Net Working Capital Days



^ ROCE – {EBIT/ (Net Worth + Borrowings)}



# Consolidated Profit & Loss Account Statement

| Particulars (Rs. Crs)                            | FY25           | FY24           | FY23           | FY22           | FY21           | FY20           |
|--|----------------|----------------|----------------|----------------|----------------|----------------|
| <b>Net Revenue from Operations</b>               | <b>3,148.5</b> | <b>2,843.9</b> | <b>3,511.0</b> | <b>3,061.2</b> | <b>2,644.9</b> | <b>2,424.8</b> |
| COGS   | 1,858.9        | 1,775.1        | 2,270.6        | 1,908.0        | 1,655.4        | 1,607.6        |
| <b>Gross Profit</b>                              | <b>1,289.6</b> | <b>1,068.9</b> | <b>1,240.3</b> | <b>1,153.2</b> | <b>989.5</b>   | <b>817.2</b>   |
| <b>Gross Profit %</b>                            | <b>41.0%</b>   | <b>37.6%</b>   | <b>35.3%</b>   | <b>37.7%</b>   | <b>37.4%</b>   | <b>33.7%</b>   |
| Employee Expenses                                | 264.7          | 232.0          | 218.4          | 202.0          | 194.3          | 179.3          |
| Other Operating Expenses                         | 392.9          | 362.3          | 355.4          | 351.3          | 308.4          | 304.7          |
| <b>Operating EBITDA</b>                          | <b>632.1</b>   | <b>474.6</b>   | <b>666.6</b>   | <b>599.9</b>   | <b>486.9</b>   | <b>333.2</b>   |
| <b>EBITDA Margin</b>                             | <b>20.1%</b>   | <b>16.7%</b>   | <b>19.0%</b>   | <b>19.6%</b>   | <b>18.4%</b>   | <b>13.7%</b>   |
| Other Income                                     | 120.1          | 95.7           | 44.9           | 26.8           | 18.6           | 10.7           |
| Depreciation                                     | 66.1           | 62.2           | 51.9           | 44.8           | 46.6           | 41.0           |
| <b>EBIT</b>                                      | <b>686.1</b>   | <b>508.1</b>   | <b>659.6</b>   | <b>581.9</b>   | <b>458.9</b>   | <b>302.9</b>   |
| <b>EBIT Margin</b>                               | <b>21.8%</b>   | <b>17.9%</b>   | <b>18.8%</b>   | <b>19.0%</b>   | <b>17.3%</b>   | <b>12.5%</b>   |
| Interest   | 5.9            | 5.1            | 5.4            | 6.2            | 5.6            | 5.5            |
| <b>Profit Before Tax &amp; Exceptional</b>       | <b>680.2</b>   | <b>502.9</b>   | <b>654.2</b>   | <b>575.7</b>   | <b>453.3</b>   | <b>297.4</b>   |
| Exceptional Item Gain / (Loss)**                 | 0.0            | 0.0            | 0.0            | 0.0            | -              | -30.9          |
| <b>Profit Before Tax</b>                         | <b>680.2</b>   | <b>502.9</b>   | <b>654.2</b>   | <b>575.7</b>   | <b>453.3</b>   | <b>266.5</b>   |
| <b>PBT Margin</b>                                | <b>21.6%</b>   | <b>17.7%</b>   | <b>18.6%</b>   | <b>18.8%</b>   | <b>17.1%</b>   | <b>11.0%</b>   |
| Tax  | 173.8          | 133.2          | 152.0          | 152.2          | 107.9          | 61.8           |
| <b>Net Profit</b>                                | <b>506.4</b>   | <b>369.7</b>   | <b>502.2</b>   | <b>423.5</b>   | <b>345.4</b>   | <b>204.7</b>   |
| <b>Net Profit Margin</b>                         | <b>16.1%</b>   | <b>13.0%</b>   | <b>14.3%</b>   | <b>13.8%</b>   | <b>13.1%</b>   | <b>8.4%</b>    |
| Other Comprehensive Income                       | -1.0           | -0.4           | 2.3            | 2.4            | 1.6            | -5.1           |
| <b>Total Comprehensive income for the period</b> | <b>505.5</b>   | <b>369.4</b>   | <b>504.5</b>   | <b>425.9</b>   | <b>347.0</b>   | <b>199.6</b>   |
| <b>EPS</b>                                       | <b>10.13</b>   | <b>7.40</b>    | <b>10.06</b>   | <b>8.49</b>    | <b>6.9</b>     | <b>4.1</b>     |

1. Appointed date for merger of ECC and SCIL is 1st Apr'18

# Consolidated Balance Sheet

| Assets (Rs. Crs)                          | Mar-25         | Mar-24         | Mar-23         | Mar-22         | Mar-21         | Mar-20         |
|---|----------------|----------------|----------------|----------------|----------------|----------------|
| <b>Non-Current Assets (A)</b>             | <b>944.1</b>   | <b>640.4</b>   | <b>581.2</b>   | <b>487.6</b>   | <b>367.6</b>   | <b>360.6</b>   |
| Property, Plant and Equipment             | 425.8          | 451.7          | 392.8          | 349.6          | 277.6          | 282.9          |
| Capital work-in-progress                  | 9.4            | 4.0            | 53.5           | 21.1           | 4.3            | 6.5            |
| Right to use an Asset                     | 63.5           | 42.5           | 33.2           | 36.4           | 31.1           | 34.9           |
| Goodwill                                  | 60.4           | 62.2           | -              | -              | -              | -              |
| Other Intangible Assets                   | 6.7            | 6.0            | 3.8            | 4.3            | 0.6            | 1.7            |
| Intangible Assets under Development       | 19.1           | 18.7           | 17.7           | 14.1           | 10.0           | 3.8            |
| <b>Non-Current Financial Assets</b>       |                |                |                |                |                |                |
| (i) Investments                           | 67.1           | 0.1            | 0.1            | 0.1            | 0.1            | 0.1            |
| (ii) Loans & other financial assets       | 247.9          | 13.8           | 36.4           | 30.8           | 6.0            | 5.3            |
| Deferred tax Asset (net)                  | 1.2            | 0.7            | -              | -              | -              | 1.1            |
| Non-Current tax Assets (net)              | 37.5           | 37.7           | 34.9           | 21.6           | 20.4           | 20.2           |
| Other non-current Assets                  | 5.7            | 2.8            | 8.7            | 9.5            | 17.6           | 4.2            |
| <b>Current Assets (B)</b>                 | <b>3,020.3</b> | <b>2,672.9</b> | <b>2,787.5</b> | <b>2,522.0</b> | <b>2,304.3</b> | <b>1,745.6</b> |
| Inventories                               | 703.7          | 610.4          | 888.7          | 937.8          | 754.4          | 588.0          |
| <b>Current Financial Assets</b>           |                |                |                |                |                |                |
| (i) Investments                           | 457.2          | 345.7          | 238.8          | 356.02         | 290.2          | 86.0           |
| (ii) Trade receivables                    | 783.4          | 715.9          | 946.1          | 843.13         | 848.2          | 849.8          |
| (iii) Cash and cash equivalents           | 38.2           | 46.6           | 46.9           | 57.25          | 213.3          | 92.6           |
| (iv) Bank balances other than (iii) above | 4.6            | 136.7          | 256.0          | 21.88          | 28.8           | 0.9            |
| (v) Loans                                 | 101.9          | 181.2          | 236.5          | 0.47           | 7.7            | 7.9            |
| (vi) Other financial assets               | 814.5          | 536.5          | 48.5           | 174.50         | 11.4           | 21.8           |
| Other Current Assets                      | 116.9          | 99.8           | 126.1          | 131.03         | 150.3          | 98.6           |
| <b>Total Assets (A+B)</b>                 | <b>3,964.4</b> | <b>3,313.3</b> | <b>3,368.7</b> | <b>3,009.6</b> | <b>2,671.9</b> | <b>2,106.2</b> |

| Equity & Liabilities (Rs. Crs)                | Mar-25         | Mar-24         | Mar-23         | Mar-22         | Mar-21         | Mar-20         |
|---|----------------|----------------|----------------|----------------|----------------|----------------|
| <b>EQUITY (A)</b>                             | <b>2,905.1</b> | <b>2,444.5</b> | <b>2,381.8</b> | <b>1,927.2</b> | <b>1,541.3</b> | <b>1,221.8</b> |
| Equity Share Capital                          | 499.1          | 499.1          | 499.1          | 499.1          | 499.1          | 499.1          |
| Other Equity                                  | 2,402.0        | 1,942.4        | 1882.6         | 1428.1         | 1,042.2        | 722.6          |
| Non-controlling Interests                     | 3.9            | 3.0            | 0.0            | 0.0            | 0.1            | 0.0            |
| <b>Non-Current liabilities (B)</b>            | <b>94.2</b>    | <b>68.0</b>    | <b>53.9</b>    | <b>61.0</b>    | <b>49.6</b>    | <b>44.5</b>    |
| <b>Non-current Financial liabilities</b>      |                |                |                |                |                |                |
| Lease Liabilities                             | 32.8           | 18.5           | 17.7           | 24.7           | 15.3           | 19.4           |
| Provisions                                    | 34.8           | 25.9           | 22.6           | 22.3           | 29.2           | 25.1           |
| Deferred tax liabilities (net)                | 26.6           | 23.6           | 13.6           | 13.9           | 5.0            | -              |
| Non-current Tax Liabilities                   | -              | -              | -              | -              | -              | -              |
| <b>Current liabilities (C)</b>                | <b>965.2</b>   | <b>800.7</b>   | <b>933.0</b>   | <b>1,021.4</b> | <b>1,081.0</b> | <b>839.9</b>   |
| <b>Current Financial liabilities</b>          |                |                |                |                |                |                |
| (i) Borrowings                                | 0.0            | 0.5            | -              | -              | -              | -              |
| (ii) Trade Payables                           | 489.4          | 430.0          | 490.2          | 517.2          | 591.2          | 490.9          |
| (iii) Lease Liabilities                       | 19.1           | 11.2           | 16.2           | 12.9           | 17.3           | 16.2           |
| (iii) Other financial liabilities             | 377.3          | 294.8          | 366.2          | 399.7          | 356.8          | 235.4          |
| Other current liabilities                     | 64.7           | 53.2           | 51.2           | 79.8           | 108.2          | 80.2           |
| Provisions                                    | 9.0            | 10.4           | 6.3            | 7.2            | 5.6            | 9.7            |
| Current tax liabilities                       | 5.6            | 0.5            | 2.8            | 4.7            | 1.9            | 7.4            |
| <b>Total Equity &amp; Liabilities (A+B+C)</b> | <b>3,964.4</b> | <b>3,313.3</b> | <b>3,368.7</b> | <b>3,009.6</b> | <b>2,671.9</b> | <b>2,106.2</b> |

# Consolidated Working Capital Movement

| Particulars (Rs. Crs)  | Mar-25       | Mar-24       | Mar-23       | Mar-22       | Mar-21       | Mar-20       |
|--|--------------|--------------|--------------|--------------|--------------|--------------|
| Inventory (A)  | 703.7        | 610.4        | 888.7        | 937.8        | 754.4        | 588.0        |
| <i>Inventory Days (Inventories/ COGS*365) (i)</i>                                      | 138          | 126          | 143          | 179          | 166          | 134          |
| Trade Receivables (B)  | 783.4        | 715.9        | 946.1        | 843.1        | 848.2        | 849.8        |
| <i>Trade Receivables Days (Trade Receivables / Revenue*365) (ii)</i>                   | 91           | 92           | 98           | 100          | 117          | 128          |
| Trade Payables (C)   | 489.4        | 430.0        | 490.6        | 517.2        | 598.3        | 490.9        |
| <i>Trade Payables Days (Trade Payables/ COGS*365) (iii)</i>                            | 96           | 88           | 79           | 99           | 132          | 111          |
| Other Financial Liabilities (D)  | 377.3        | 294.8        | 366.2        | 399.7        | 349.8        | 235.4        |
| <i>Other Financial Liabilities Days (Other Current Liabilities / Revenue*365) (iv)</i> | 44           | 38           | 38           | 48           | 48           | 35           |
| <b>Net Working Capital (A+B-C-D)</b>   | <b>620.3</b> | <b>601.5</b> | <b>978.0</b> | <b>864.0</b> | <b>654.5</b> | <b>711.4</b> |
| <i>Net Working Capital Days (i + ii – iii – iv)</i>                                    | 89           | 91           | 124          | 133          | 103          | 115          |



# Consolidated Cash Flow Statement

| Particulars (Rs. Crs)   | Year ended<br>31-Mar-25 | Year ended<br>31-Mar-24 | Year ended<br>31-Mar-23 | Year ended<br>31-Mar-22 | Year ended<br>31-Mar-21 | Year ended<br>31-Mar-20 |
|---|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| <b>Net Profit Before Tax</b>  | <b>680.2</b>            | <b>502.9</b>            | <b>654.2</b>            | <b>575.7</b>            | <b>453.3</b>            | <b>266.5</b>            |
| Adjustments for: Non-Cash Items / Other Investment or Financial Items | -45.6                   | -6.7                    | 38.5                    | 46.3                    | 54.5                    | 45.7                    |
| <b>Operating profit before working capital changes</b>                | <b>634.7</b>            | <b>496.3</b>            | <b>692.7</b>            | <b>622.0</b>            | <b>507.8</b>            | <b>312.2</b>            |
| Changes in working capital  | -18.0                   | 392.6                   | -135.2                  | -257.6                  | 25.6                    | -9.4                    |
| <b>Cash generated from Operations</b>                                 | <b>616.6</b>            | <b>888.8</b>            | <b>557.5</b>            | <b>364.4</b>            | <b>533.4</b>            | <b>302.8</b>            |
| Direct taxes paid (net of refund)                                     | 163.9                   | 129.0                   | 168.1                   | 142.6                   | 107.9                   | 81.4                    |
| <b>Net Cash from Operating Activities</b>                             | <b>452.7</b>            | <b>759.8</b>            | <b>389.4</b>            | <b>221.8</b>            | <b>425.4</b>            | <b>221.4</b>            |
| <b>Net Cash from Investing Activities</b>                             | <b>-392.1</b>           | <b>-431.7</b>           | <b>-327.2</b>           | <b>-290.2</b>           | <b>-282.7</b>           | <b>-117.9</b>           |
| <b>Net Cash from Financing Activities</b>                             | <b>-69.1</b>            | <b>-328.3</b>           | <b>-72.5</b>            | <b>-62.6</b>            | <b>-47.1</b>            | <b>-61.4</b>            |
| <b>Net Increase /(Decrease) in Cash and Cash equivalents</b>          | <b>-8.4</b>             | <b>-0.3</b>             | <b>-10.4</b>            | <b>-131.1</b>           | <b>95.7</b>             | <b>42.2</b>             |
| Add: Cash & Cash equivalents at the beginning of the period           | 46.6                    | 46.9                    | 57.2                    | 188.3                   | 92.6                    | 50.5                    |
| <b>Cash &amp; Cash equivalents at the end of the period</b>           | <b>38.2</b>             | <b>46.6</b>             | <b>46.9</b>             | <b>57.2</b>             | <b>188.3</b>            | <b>92.6</b>             |

# Key Takeaways

|   |  |  |  |
|---|--|--|--|
| <b>Formidable Player in the Indian Agro-chem Space</b> <ul style="list-style-type: none"> <li>Strong / leadership position across products and processes</li> <li>Ability to develop new combination products</li> </ul>  | <b>Experienced Management Team and Board of Directors</b> <ul style="list-style-type: none"> <li>Strong management and autonomous Board with vast experience and domain expertise</li> <li>Localized experience enables better understanding of market needs to drive growth</li> </ul>  | <b>Well-diversified Product Portfolio Across Agro-Chem Value Chain</b> <ul style="list-style-type: none"> <li>Multi-product, multi-geography, multi-customer de-risking</li> <li>Access to an impressive range of own actives along with significant exposure towards speciality products resulting in product offerings at all price points serving multiple customers sub-segment</li> </ul> | <b>Strong Brand and Well-Entrenched Distribution Network</b> <ul style="list-style-type: none"> <li>26 states, 60 depots, 15,000+ distributors, 40,000+ dealer network</li> <li>High credibility and brand recall amongst farmers and the trade on account of transparent and ethical business dealings</li> </ul> |
| <b>To Benefit from Strong Parentage of SCC Japan</b> <ul style="list-style-type: none"> <li>Benefits from international standing of SCC Japan; most well revered brand renowned for its quality</li> <li>Access to SCC's global supply chain and global R&amp;D activities (one of the largest spenders) resulting in development of actives and broad range of formulation research</li> </ul> | <b>State-of-the-art Manufacturing and R&amp;D Facilities</b> <ul style="list-style-type: none"> <li>Operates five manufacturing facilities with state-of-the-art plants at strategic location which helps reduce logistic time and costs</li> <li>Capacity not a constraint allowing for significant growth on existing investments</li> </ul> | <b>Strong Track Record of Driving Growth</b> <ul style="list-style-type: none"> <li>Grown 14X over FY11-25 driven by organic and inorganic expansion</li> <li>Debt free balance sheet with strong return ratios</li> </ul>   |  |

# Annexures

Glance of various events to bring people together

---









# 'Every Day Farmers' Day' Campaign



ONE TEAM...ONE MISSION... ONE CAMPAIGN





# 'Every Day Farmers' Day' Campaign


















# Glance of various events to bring people together



Strategic Workshop of senior and middle management to deliberate on growth acceleration



Logo for Annual Sales Team meeting - Manthan means joint efforts to squeeze out the results



Logo for Annual Distributors meeting - Bandhan means strong bonding



Logo showing Core Values

For further information, please contact:

| Company :   | Investor Relations Advisors :   |
|---|---|
| Sumitomo Chemical India Limited<br><br>CIN: L24110MH2000PLC124224<br><br><a href="mailto:investor.relations@sumichem.co.in">investor.relations@sumichem.co.in</a> | Strategic Growth Advisors Pvt. Ltd.<br><br>CIN: U74140MH2010PTC204285<br><br>Mr. Jigar Kavaiya / Mr. Parin Narichania<br>+91 99206 02034 / +91 99300 25733<br><a href="mailto:jigar.kavaiya@sgapl.net">jigar.kavaiya@sgapl.net</a> / <a href="mailto:parin.n@sgapl.net">parin.n@sgapl.net</a><br><br><a href="http://www.sgapl.net">www.sgapl.net</a> |

For further information, kindly visit our new website  
[www.sumichem.co.in](http://www.sumichem.co.in)

